Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07179055 · ClinicalTrials.gov registry record · Phase 2
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
A Phase 2 study of Dry Eye, sponsored by Vanda Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 5
- Study locations
NCT07179055 is a Phase 2 study of Dry Eye that is actively recruiting participants, run by Vanda Pharmaceuticals. The registered enrollment target is 160 participants, above the 92-participant average among 41 other Dry Eye trials with a reported enrollment target (74% higher). The trial reports 5 study locations across 5 states.
The verdict
NCT07179055, a Phase 2 study of Dry Eye, is actively recruiting participants, sponsored by Vanda Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VSJ-110
Study Locations (5)
California
- Vanda Investigational Site - Newport Beach
Massachusetts
- Vanda Investigational Site - Andover
North Carolina
- Vanda Investigational Site - Shelby
Tennessee
- Vanda Investigational Site - Memphis
Virginia
- Vanda Investigational Site - Lynchburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2025-10 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07179055
The ClinicalTrials.gov registry entry for NCT07179055 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 92-participant average among 41 other Dry Eye trials with a reported enrollment target (74% higher). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dry Eye appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07179055 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Massachusetts, North Carolina.
Frequently Asked Questions
What is clinical trial NCT07179055 about?
NCT07179055 is a clinical study titled "An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye". The purpose of this study is to determine the safety and efficacy of VSJ-110 compared to placebo in the treatment of dry eye.
What is the current status of trial NCT07179055?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2025-10. Estimated completion is 2026-09.
What conditions does trial NCT07179055 study?
This clinical trial studies the following conditions: Dry Eye.
What interventions are being tested in trial NCT07179055?
The interventions under investigation include: Placebo (DRUG), VSJ-110 (DRUG).
Who is sponsoring clinical trial NCT07179055?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07179055 being conducted?
This trial has 5 study locations across California, Massachusetts, North Carolina, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dry Eye
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
RECRUITING · Phase 2
-
Phase 2b Controlled Study of Dosing Techniques - Part B
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease
COMPLETED · Phase 2
-
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
COMPLETED · Phase 2
-
Can Pregabalin Reduce the Frequency and Severity of Dry Eye Symptoms After Laser-assisted in Situ Keratomileusis?
COMPLETED · Phase 2
-
Treatment of Patients With Blepharitis and Facial Rosacea
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.